Malignant pleural mesothelioma (MPM) Cancer Mesothelioma of pleura
Conditions
Interventions
The symptoms will be measured using validated questionnaires at end of radiotherapy treatment (week 1), at week 5 and week 12 (final study visit)
Sponsors
NHS Greater Glasgow and Clyde (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. >/=18 years of age. 2. Histological or multi-disciplinary team (MDT) diagnosis of mesothelioma 3. Able to complete study assessments 3. Life expectancy of at least 3 months based on clinical judgement 4. Due to receive radiotherapy for pain resulting from mesothelioma (defined as index site ? site of radiotherapy) 5. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2 6. CT scan within 6 weeks of radiotherapy 7. Worst pain >4/10 (0-10 Visual Analogue Scale) corresponding to the index site
Exclusion criteria
Exclusion criteria: 1. Received chemotherapy or radiotherapy in the preceding six weeks that is likely to alter pain at the index site during the duration of the study 2. Planned chemotherapy during the period of the study that is likely to alter pain during the course of the study 3. Psychotic disorders or cognitive impairment 4. Co-existing lung tumours at the time of study entry 5. Pregnant or breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| This research will assess if radiotherapy is beneficial in treating pain in malignant pleural mesothelioma (MPM). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To assess whether radiotherapy improves other symptoms (dyspnoea, fatigue, distress) using a number of validated questionnaires 2. Possible biomarkers will be examined and the relationship between inflammation and symptoms explored | — |
Countries
Scotland, United Kingdom
Outcome results
None listed